Drugs / PolyMVA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04557410 | Sep 2020 → May 2021 | amyotrophic lateral sclerosis | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 1 | NCT01833273 | Jul 2010 → Oct 2013 | brain glioblastoma | Stony Brook University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Poly MVA | “In this study, we want to find out more about a dietary supplement, called Poly MVA (also called the study drug in this form), for people with ALS.” NCT04557410 ↗ |
| Modality | Other / unclassified | “This supplement, PolyMVA, is a uniquely formulated combination of minerals, vitamins, and amino acids.” NCT01833273 ↗ |
| Route | Oral | “Subjects will take 8 tsp/day of PolyMVA over a 26 week period” NCT01833273 ↗ |